

Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K

NEKTAR THERAPEUTICS  
Form 8-K  
April 22, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 22, 2003

NEKTAR THERAPEUTICS  
(Exact name of Registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

0-23556  
(Commission  
File Number)

94-3134940  
(IRS Employer  
Identification No.)

150 Industrial Road  
San Carlos, California 94070  
(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (650) 631-3100

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

(c) Exhibits

Exhibit 99.1: Press Release Dated April 22, 2003

Item 9. Regulation FD Disclosure

This Form 8-K is being furnished to report information pursuant to Item 12  
"Results of Operations and Financial Condition." Please see Item 12 below.

## Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K

### Item 12. Results of Operations and Financial Condition

On April 22, 2003, Nektar Therapeutics issued a press release announcing results for the quarter ended March 31, 2003. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

#### SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

By: /s/ AGIT S. GILL  
-----

Ajit S. Gill  
Chief Executive Officer,  
President and Director

Date: April 22, 2003

By: /s/ AJAY BANSAL  
-----

Ajay Bansal  
Chief Financial Officer, and Vice  
President, Finance and  
Administration

Date: April 22, 2003

#### EXHIBIT INDEX

##### Exhibit No. Description

99.1 Earnings Press Release of Nektar Therapeutics dated April 22, 2003.